Simulations Plus, Nvidia collaborate to scale AI-assisted modeling workflows

Simulations Plus (SLP) announced the launch of a technical collaboration with NVIDIA (NVDA) focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simulations Plus’ validated scientific engines across physiologically-based pharmacokinetics, pharmacokinetics/pharmacodynamics, and quantitative systems pharmacology with NVIDIA AI infrastructure to accelerate and scale simulation cycles, parameter exploration, and virtual population studies. Together, these capabilities address two core constraints in model-informed drug development: reducing manual, expertise-driven work and enabling large-scale exploration of model structures and parameters in parallel-shifting modeling from a sequential process to a more iterative, data-informed workflow operating at program-relevant timelines.

Claim 55% Off TipRanks